JP Morgan Chase
IBRX icon

JP Morgan Chase’s ImmunityBio IBRX Stock Holding History

JP Morgan Chase’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,200
Closed -$291K – 7544
2024
Q1 		$291K Buy
+54,200
New +$245K ﹤0.01% 5117

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

JP Morgan Chase's IBRX Position: Q1 2026 in Review

JP Morgan Chase increased its ImmunityBio (IBRX) stake by 22% in Q1 2026, buying an estimated $1.85M and bringing the position to 1,489,509 shares worth $9.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

JP Morgan Chase first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $12.9M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • JP Morgan Chase held 1,489,509 shares of ImmunityBio worth $9.92M as of Q1 2026.
  • JP Morgan Chase bought 269,630 ImmunityBio shares in Q1 2026, an estimated $1.85M.
  • ImmunityBio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2679 holding.
  • JP Morgan Chase first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's ImmunityBio position peaked at $12.9M in Q1 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.